Table 2 Patients characteristics of thromboembolic risk factors of the European studies
Study 1 | Study 2 | |||
|---|---|---|---|---|
n (%) | Drospirenone | Drospirenone | Desogestrel | |
(N = 713) | (N = 858) | (N = 332) | ||
Age, mean (SD), yr | 28.7 (7.1) | 28.9 (7.1) | 28.9 (7.1) | |
Age group | ≤35 yr | 569 (79.8) | 682 (79.5) | 259 (78.0) |
> 35 yr | 144 (20.2) | 176 (20.5) | 73 (22.0) | |
BMI, mean (SD) (kg/m2) | 23.0 (3.8) | 23.0 (3.5) | 22.8 (3.9) | |
BMI group | < 30 | 672 (94.2) | 828 (96.5) | 316 (95.2) |
≥30 | 41 (5.8) | 30 (3.5) | 16 (4.8) | |
BP group (mm Hg) | SBP < 130, DBP < 85 | 571 (80.1) | 727 (84.7) | 290 (87.3) |
SBP ≥130, DBP ≥85 | 142 (19.9) | 131 (15.3) | 42 (12.7) | |
Presence of ≥1 VTE risk factor | 110 (15.4) | 142 (16.5) | 59 (17.8) | |
Current smoker | 182 (25.5) | 237 (27.6) | 103 (31.0) | |
Regular menstrual bleeding during the last 6 cycles | 680 (95,4) | 786 (91.6) | 305 (91.9) | |
Prior treatment with sex hormones and modulators of genital system | 455 (63,8) | 704 (82.1) | 288 (86.7) | |
Starters | 287 (40.3) | 417 (48.6) | ||